Scientists investigating the impact on mice of the chemotherapy drug temozolomide (TMZ), used to treat patients with brain cancer, have found it induces behavioural and psychological changes relevant to depression.
Funding for the MECPST-IPD project to Dr Martin Egeland, at Kings College London, UK, supported research into the impact of the drug temozolomide on neurogenesis and the relationship between depleted neurogenesis and depression. A paper he co-authored, presenting the team’s findings, has now been published in the ‘Journal of Translational Psychiatry’.